The following is a structured summary of Beacon Pharmaceuticals’ published Tagrix prescribing information. It is not a replacement for the complete current product document.
Composition
Tagrix 80 contains osimertinib mesylate equivalent to 80 mg osimertinib.
Dosage
The cited Beacon information recommends 80 mg once daily and states that treatment continues until disease progression or unacceptable toxicity for the indication described in that document.
Administration
Tagrix may be taken with or without food.
Dose modification
The product information provides dose modification for:
- ILD/pneumonitis
- QTc prolongation
- Left ventricular ejection fraction decline
- Symptomatic heart failure
- Grade 3 or higher adverse reactions
Depending on the event, treatment may be withheld, resumed at 40 mg or 80 mg, or permanently discontinued.
Important interactions
Strong CYP3A inducers should be avoided. Other sensitive drug substrates may also require consideration.
Storage
Beacon states that Tagrix should be stored in a cool, dry place away from light and kept out of reach of children.
Manufacturer
Beacon’s prescribing information identifies BEACON Pharmaceuticals Limited, Mymensingh, Bangladesh as the manufacturer and describes the product as for export.